The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population

Archives of Gerontology and Geriatrics

Volumn 43, Issue 2, 2006, Pages 187-192

  Santangelo, Antonino ^a   Testai, Manuela ^a   Barbagallo, Patrizia ^a   Manuele, Sara ^a   Di Stefano, Alessandra ^a   Tomarchio, Marcello ^a   Trizzino, Giorgio ^a   Musumeci, Giovanni ^a   Panebianco, Pietra ^a   Maugeri, Domenico ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bone metastases; Clodronate; Palliative cures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

AGED; ANALGESIA; ARTICLE; BARTHEL INDEX; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FOLLOW UP; HOME CARE; HUMAN; LIFE EXPECTANCY; PALLIATIVE THERAPY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; TERMINALLY ILL PATIENT; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLODRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PAIN; PALLIATIVE CARE; QUALITY OF LIFE; SURVIVAL ANALYSIS; TERMINALLY ILL; TREATMENT OUTCOME;

EID: 33747160801     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2005.10.006     Document Type: Article

References (28)

1. Arican A., Icli F., Akbulut H., Cakir M., Sencan O., Samur M., Acikgoz N., and Demir-Kazik A. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med. Oncol. 16 (1999) 204-210
2. Brown J.E., Neville-Webbe H., and Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer 11 (2004) 207-224
3. Chlebowski R.T. Bone health in women with early-stage breast cancer. Clin. Breast Cancer 5 Suppl. 2 (2005) S35-S40
4. Clemons M., and Verma S. Should oral bisphosphonates be standard of care in women with early breast cancer?. Breast Cancer Res. Treat. 90 (2005) 315-318
5. Coleman R.E. The role of bisphosphonates in breast cancer. Breast 13 Suppl. 1 (2004) S19-S28
6. Coleman R.E. Bisphosphonates in breast cancer. Ann. Oncol. 16 (2005) 687-695
7. Conte P., and Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin. Oncol. 31 Suppl. 10 (2004) 59-63
8. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl. 4 (2004) 28-37
9. Crooks V., Waller S., Smith T., and Hahn T.J. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J. Gerontol. 46 (1991) 139-144
10. Freyer G., Ligneau B., and Trillet-Lenoir V.V. Palliative hormone therapy, low-dose chemotherapy, and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia: report of a pilot experience. Eur. J. Intern. Med. 11 (2000) 329-333
11. Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin. Breast Cancer 5 Suppl. 2 (2005) S54-S62
12. Kaplan R.M., Bush J.W., and Berry C.C. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med. Care 17 (1979) 501-525
13. Karnofsky D.A. Why prolong the life of a patient with advanced cancer?. CA Cancer J. Clin. 10 (1960) 9-12
14. Katz S., Downs T.D., Cash H.R., and Grotz R.C. Progress in development of the index of ADL. Gerontologist 10 (1970) 20-30
15. Lawton M.P., and Brody E.M. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 9 (1969) 179-186
16. Leppa S., Saarto T., Vehmanen L., Blomqvist C., and Elomaa I. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res. Treat. 90 (2005) 117-125
17. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin. Emerg. Drugs 8 (2003) 469-488
18. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist 9 Suppl. 4 (2004) S38-S47
19. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel Index. Md. State Med. J. 14 (1965) 61-65
20. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., and Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer 113 (2005) 364-371
21. Parker C.C. The role of bisphosphonates in the treatment of prostate cancer. Br. J. Urol. Int. 95 (2005) 935-938
22. Romanus D., Iscoe N., Deangelis C., Shear N., and Einarson T.R. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Support Care Cancer 12 (2004) 844-851
23. Saarto T., Vehmanen L., Virkkunen P., and Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43 (2004) 650-656
24. Saba N., and Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1. Mechanisms of action, role of biomarkers and preclinical applications. Oncology 68 (2005) 10-17
25. Serkies K., Jereczek-Fossa B., Badzio A., and Jassem J. Clodronate in the management of bone metastases: a clinical study of 91 patients. Neoplasma 46 (1999) 317-322
26. Vehmanen L., Saarto T., Risteli J., Risteli L., Blomqvist C., and Elomaa I. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res. Treat. 87 (2004) 181-188
27. WHO, 1999. Cancer Pain and Palliative Care Program. Cancer Pain Release, vol. 13.
28. Wong, R., Wiffen, P.J., 2002. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. CD002068.